Atabak Mokari - 01 Sep 2026 Form 4 Insider Report for CORCEPT THERAPEUTICS INC (CORT)

Reporting relationship: Chief Financial Officer
Issuer ticker: CORT
Reported as of: 01 Sep 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Sep 2026, 21:06:51 UTC
Prior SEC filing: 03 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Joseph Douglas Lyon, as attorney-in-fact for Atabak Mokari

Key filing fact

Atabak Mokari filed Form 4 for CORCEPT THERAPEUTICS INC (CORT) on 03 Sep 2026.

Key facts

This page summarizes Atabak Mokari's Form 4 filing for CORCEPT THERAPEUTICS INC (CORT).
3 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 03 Sep 2026, 21:06.

Change

Previous filing in this sequence was filed on 03 Aug 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001678419 Primary reporting owner

Mokari Atabak

Relationship: Chief Financial Officer
Address: C/O CORCEPT THERAPEUTICS INCORPORATED, 101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Signature: /s/ Joseph Douglas Lyon, as attorney-in-fact for Atabak Mokari
Signature date: 03 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CORT transaction

Common Stock

Award

Transaction value
Shares: +138
Change %: +0.86%
Price: $113.38^*
Shares after: 16,268
Date: 01 Sep 2026
Ownership: Direct
Footnotes: F1, F2, F3

CORT transaction

Common Stock

Award

Transaction value
Shares: +138
Change %: +0.85%
Price: $0.000000^*
Shares after: 16,406
Date: 01 Sep 2026
Ownership: Direct
Footnotes: F3, F4

CORT transaction

Common Stock

Tax liability

Transaction value
Shares: -102
Change %: -0.62%
Price: $113.38^*
Shares after: 16,304
Date: 02 Sep 2026
Ownership: Direct
Footnotes: F5, F6, F7

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 7 footnotes

Footnote F1

The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on September 1, 2026.

Footnote F2

In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.

Footnote F3

Includes 200 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 397 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

Footnote F4

Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.

Footnote F5

These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.

Footnote F6

The closing price on September 1, 2026 was used to calculate the withholding obligation.

Footnote F7

Includes 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 397 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

SEC remarks

The power of attorney under which this form was signed is on file with the Commission.